A Agilent Technologies Inc.

Agilent Receives Multiple Innovation Awards

(NYSE: A) today announced that both the NanoDis System and the innovative new style polychromator in the 5800 and 5900 ICP-OES have received Innovation Awards from

The recently launched NanoDis System utilizes cross-flow filtration—a concept traditionally used in industrial process chemistry—combined with conventional dissolution instruments to enable nanoparticle dissolution testing. Along with the introduction of automation for the complete workflow, the novel new system improves the process of introducing new drugs to market.

“The overwhelmingly positive response for the NanoDis System from the dissolution community has been quite remarkable,” said Michael Frank, associate vice president of global marketing, Agilent Liquid Phase Separation Division. “At Agilent, we strive to deliver products that support scientists and their need to prove reliable results in an efficient and effective way, which is exactly what the NanoDis System delivers.”

Design changes to the Agilent ICP-OES polychromator have improved the analytical performance of the latest Agilent ICP-OES instruments released earlier this year by lowering detection limits and improving spectral resolution. This modernization has not only improved the performance of the instrument but has also dramatically reduced the footprint and Argon gas consumption, making it a more sustainable option for laboratories.

“The new design of the polychromator is a real game-changer for our ICP-OES instruments moving forward, raising the bar for elemental analysis,” commented Keith Bratchford, vice president and general manager, Agilent Spectroscopy. “Receiving an Innovation Award from The Analytical Scientist is a testament to the great work that our R&D teams do, striving to continually find ways to improve the performance of our instruments.”

Through advancements like these, including Agilent’s Vaya Raman spectrometer for pharma QA/QC, which as well as being a gold winner in the R&D 100 awards, is also a finalist in Innovation Awards, Agilent is enacting its commitment to advancing the quality of life and progressing science. Agilent instruments and technologies help scientists to further disease research, develop advanced therapies, and ensure our water, food, air, and fuels are clean. The discoveries Agilent enables makes the world a better place to live.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal 2020 and employs 16,400 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, subscribe to the Agilent . Follow Agilent on , , and .

EN
14/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch